Have not listened to the CC for Celgene but a couple of interesting points on the news release:
1. They will have data on Phase 3 tests with Vidaza in AML this year.
2. Vidaza sales continue strong with most of the growth coming from international sales.
They had great earnings and I expect dacogen will also be positive and sales will not decline.